<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002211</url>
  </required_header>
  <id_info>
    <org_study_id>228E</org_study_id>
    <secondary_id>0073</secondary_id>
    <nct_id>NCT00002211</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients</brief_title>
  <official_title>An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens in HIV-1 Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacia and Upjohn</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give combinations of three&#xD;
      or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine&#xD;
      (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label study. Patients are stratified by HIV-1 RNA levels (20,000&#xD;
      to 200,000 copies/ml and greater than 200,000 copies/ml). Patients are equally randomized to&#xD;
      one of four groups and receive antiretroviral therapy for 24 weeks. Group 1 receives&#xD;
      delavirdine (DLV) plus nelfinavir (NFV) plus stavudine (d4T). Group 2 receives DLV plus NFV&#xD;
      plus didanosine (ddI). Group 3 receives NFV plus d4T plus ddI. Group 4 receives DLV plus NFV&#xD;
      plus d4T plus ddI. Patients are evaluated for drug safety and viral burden. Patients may opt&#xD;
      to continue on the study for 24 additional weeks, at the discretion of the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>160</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delavirdine mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        You may be eligible for this study if you:&#xD;
&#xD;
          -  Are at least 18 years old.&#xD;
&#xD;
          -  Are HIV-positive.&#xD;
&#xD;
          -  Have a CD4 count of at least 50 cells/mm3.&#xD;
&#xD;
          -  Have a viral load of at least 20,000 copies/ml.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        You will not be eligible for this study if you:&#xD;
&#xD;
          -  Have taken d4T.&#xD;
&#xD;
          -  Have taken protease inhibitors, including NFV.&#xD;
&#xD;
          -  Have taken nonnucleoside reverse transcriptase inhibitors.&#xD;
&#xD;
          -  Have taken ddI for 1 month or more.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmacia &amp; Upjohn</name>
      <address>
        <city>Peapack</city>
        <state>New Jersey</state>
        <zip>07977</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2000</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Stavudine</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Delavirdine</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Viral Load</keyword>
  <keyword>Nelfinavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Delavirdine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

